ClinicalTrials.gg
CompletedNCT01819727Prism301Updated Feb 26, 2019Results posted

An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

A Phase 3 interventional study of BMN 165 in Phenylketonuria, sponsored by BioMarin Pharmaceutical. Completed at 31 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.

Enrollment
Largest of 10
261 · median 39
Started
2013
with 1 other
Phase 3
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
10 of 10
BioMarin Pharmaceutical

Among the 10 studies testing pegvaliase in Phenylketonurias, this one has the largest enrollment, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 6th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegvaliase

pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegvaliase in Phenylketonurias, or all of them as a file.
02

Study summary

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in patients 18 to 70 years old with hyperphenylalaninemia due to PKU. Study BMN 165-301 is a Phase 3, open-label, randomized study designed to further characterize the safety of BMN 165 during two induction, titration, and maintenance dose regimens in adults with PKU who have not had previous exposure to BMN 165 (naive). Subjects will be randomized (1:1) to titrate up to one of two dose regimens. Other key features of this study are the dose regimens chosen for induction and titration; the study duration; self administration of study drug; and the chosen tertiary objectives.

Read the detailed description

Primary and Secondary Outcomes:

The primary objective of the study is the following:

  • To characterize the safety and tolerability during induction, titration, and maintenance dosing in BMN 165-naïve subjects who self administer BMN 165 at dose levels of 20 mg/day and 40 mg/day

The secondary objective of the study is the following:

  • To evaluate blood Phe concentration during induction, titration, and maintenance dosing in BMN 165-naïve subjects who self administer BMN 165 at dose levels of 20 mg/day and 40 mg/day

The tertiary objectives of the study are the following:

  • Percentage of daily recommended intake for age of natural protein intake
  • Dietary protein intake from medical food and intact food
  • The ADHD-RS score (-Investigator Rated; inattentive subscale score, total score, and hyperactivity/impulsivity subscale score)
  • POMS scores (-Observer Rated and -Subject Rated)
  • Trough plasma concentrations of BMN 165

Primary Analysis:

All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). The incidence of AEs will be summarized by system organ class, preferred term, relationship to study drug, and severity for the subjects who are randomized to the 40 mg/day dose, the 20 mg/day dose, and overall. A by-subject listing will be provided for those subjects who experience an SAE, including death, or experience an AE associated with early withdrawal from the study or study drug. Hypersensitivity AEs and AEs that result in dosing interruption or dose reduction are of interest, and the percentage of subjects who report these AEs will be presented.

Clinical laboratory data will be summarized by the type of laboratory test for the subjects who are randomized to the 40 mg/day dose, the 20 mg /day dose, and overall. Frequency and percentage of subjects who experience abnormal (ie, outside of reference range) and/or clinically significant abnormalities after study drug administration will be presented for each clinical laboratory test. For each clinical laboratory test, descriptive statistics will be provided for baseline and all subsequent post-baseline visits. Changes from baseline to the post-baseline visits will also be provided. Descriptive statistics, including clinically significant changes from baseline, of vital signs, physical examination results, ECG test results, and immunogenicity test results will also be provided in a similar manner. Additionally, antibodies and titers will be summarized at the scheduled time point.

Detailed statistical methods will be provided in the Statistical Analysis Plan (SAP).

Secondary Analysis:

The secondary efficacy endpoint is change from baseline to end of study in blood Phe concentration.

Baseline is defined as the average of blood Phe concentrations collected prior to dosing at the Screening Visit and on Day 1.

The primary analysis method for the secondary endpoint will use a repeated measures model, with change from baseline Phe as the dependent variable and dose (40 mg/day or 20 mg/day), study week, and baseline Phe as independent variables.

A responder analysis will be presented as a cumulative distribution function. The percentage of subjects with blood Phe concentration below "X" umol/L at the end of the study will be plotted and summarized for various "X" as a cumulative distribution function for each of the 2 doses and overall.

Detailed statistical methods will be provided in the SAP.

Tertiary Analyses:

The statistical analysis method for tertiary endpoints (protein intake; the ADHD-RS IV score) will be descriptive. More details regarding the analysis methods for the tertiary endpoints will be provided in the SAP.

Trough plasma concentrations of BMN 165 will be evaluated.

DMC The Data Monitoring Committee (DMC) will act in an advisory capacity to

BioMarin to monitor subject safety and the efficacy of BMN 165 in subjects who participate in Study BMN 165-301 .The DMC responsibilities may include the following:

  • Review the study protocol, informed consent and assent documents, and plans for data monitoring
  • Evaluate the progress of the trial; study data quality; timeliness; subject recruitment, accrual and retention; subjects' risk versus benefit; and other factors that could affect the study outcome
  • Consider relevant information that may have an effect on the safety of the participants or the ethics of the study
  • Protect the safety of the study participants in accordance with the stopping rules as defined in study protocol
  • Make recommendations to BioMarin concerning continuation or termination of the study or other modifications of the study based on their observations
  • If appropriate, conduct interim analysis of safety and efficacy
03

Conditions studied

  • Phenylketonuria

Browse trials for

Keywords

  • PKU
  • PEG-PAL
  • BioMarin
  • rAv-PAL PEG
  • BMN 165
  • open label
  • Prism301
  • Pegvaliase
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals eligible to participate in this study must meet all of the following criteria:

  • A current diagnosis of PKU with the following:

    • Current blood Phe concentration >600 µmol/L at screening and
    • Average blood Phe concentration of >600 µmol/L over the past 6 months (per available data)
  • Have no previous exposure to BMN 165
  • Are ≥18 and ≤70 years of age at the time of screening

    • Subjects who are \< 18 years of age but are already enrolled into the study may continue to participate
  • If taking Kuvan, have a treatment end date ≥14 days prior to Day 1 (ie, first dose of BMN 165)
  • Are willing and able to provide written, signed after the nature of the study has been explained and prior to any research-related procedures
  • Are willing and able to comply with all study procedures
  • Has identified a person who is ≥ 18 years of age who has the neurocognitive and linguistic capacities to comprehend and complete the POMS-Observer-rated scale
  • Has identified a competent person or persons who are ≥ 18 years of age who can observe the subject during study drug administration and for a minimum of 1 hour following administration until dose titration has completed and if needed upon return to dosing after an AE and per investigator determination.

    • A home healthcare nurse may perform the study drug observations.
  • For females of , must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study. (Females are considered not of childbearing potential if they have been in menopause for at least 2 years, have had a tubal ligation at least 1 year prior to screening, or have had a total hysterectomy.)
  • If sexually active, must be willing to use 2 acceptable methods of while participating in the study and 4 weeks after the study.

    • Males post vasectomy 2 years with no known pregnancies for at least 2 years do not need to use any other forms of birth control during the study.
    • Females who have been in menopause for at least 2 years, have had a tubal ligation at least 1 year prior to screening, or have had a total hysterectomy do not need to use any other forms of contraception during the study.
  • Have received documented approval from a study dietician confirming that the subject is capable of maintaining their diet in accordance with dietary information presented in the protocol.
  • Have neurocognitive and linguistic capacities to comprehend and answer investigator's prompts for the ADHD RS- Investigator rated instrument and to complete the POMS-Subject rated scale.
  • If applicable, maintained stable dose of medication for attention deficit hyperactivity disorder (ADHD), depression, anxiety, or other psychiatric disorder for ≥8 weeks prior to enrollment and willing to maintain stable dose throughout study unless a change is medically indicated.
  • Are in generally good health, as evidenced by physical examination, clinical laboratory evaluations and tests performed at screening

Exclusion criteria

EXCLUSION CRITERIA

Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:

  • Use of any product or investigational medical device within 30 days prior to screening or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Use of any medication that is intended to treat PKU (except Kuvan), including the use of large neutral amino acids, within 2 days prior to administration of study drug Day 1 (first dose of BMN 165). Note: Kuvan treatment must be stopped ≥14 days before Day 1
  • Use or planned use of any injectable drugs containing PEG (other than BMN 165), including medroxyprogesterone injection, within 3 months prior to screening and during study participation
  • Known to any components of BMN 165
  • Current use of levodopa
  • A positive test for antibody, surface antigen, or antibody
  • A history of organ transplantation or on chronic therapy
  • A history of substance abuse (as defined by the [DSM IV]) in the past 12 months or current alcohol or drug abuse
  • Current participation in the Kuvan registry study (PKU Demographics, Outcomes and Safety [PKUDOS]). Patients may discontinue the PKUDOS registry trial to allow enrollment in this study
  • Pregnant or breastfeeding at screening or planning to become pregnant (self or partner) or breastfeed at any time during the study
  • Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease)
  • Major surgery planned during the study period
  • Any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or terminating early from the study
  • (ALT) concentration ≥2 times the
  • Creatinine >1.5 times the upper limit of normal.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
261 participants (actual)

Study arms

  • Active comparator
    BMN 165, 20mg/day

    Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and \> 900 μmol/L).

    Drug: BMN 165

  • Active comparator
    BMN 165, 40mg/day

    Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and \> 900 μmol/L).

    Drug: BMN 165

Interventions

  • After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.

    Also known as: rAvPAL-PEG, Pegvaliase

06

What researchers measure

Primary outcomes

  1. Number of Participants With Hypersensitivity Adverse Reaction

    Hypersensitivity AEs will be identified in two ways: * Broad Algorithmic anaphylactic reaction Standardized MedDRA Queries (SMQ) * Modified Hypersensitivity SMQ to include above additional preferred terms

    Time frame: baseline and 36 weeks

Secondary outcomes

  1. Blood Phenylalanine Concentration

    Plasma phenylalanine (Phe) concentration

    Time frame: baseline and 36 weeks

Other outcomes

  1. Dietary Phenylalanine

    All patients will complete a 3-day diet diary in order to assess dietary phenylalanine intake.

    Time frame: baseline and 36 weeks

07

Results

Posted Sep 10, 2018

Participant flow

Participant flow — Overall Study
MilestoneBMN 165, 20mg/DayBMN 165, 40mg/Day
Started131130
Completed111102
Not completed2028
Withdrew: Adverse event89
Withdrew: Death10
Withdrew: Lost to follow-up11
Withdrew: Physician decision32
Withdrew: Pregnancy10
Withdrew: Protocol violation02
Withdrew: Study terminated by sponsor01
Withdrew: Withdrawal by subject611
Withdrew: Unable to demostrate ability self-inject01
Withdrew: Quit due to lack of health benifits01

Outcome measures

PrimaryNumber of Participants With Hypersensitivity Adverse Reaction

Hypersensitivity AEs will be identified in two ways: * Broad Algorithmic anaphylactic reaction Standardized MedDRA Queries (SMQ) * Modified Hypersensitivity SMQ to include above additional preferred terms

Time frame:
baseline and 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With Hypersensitivity Adverse Reaction
ParticipantsBMN 165, 20mg/DayBMN 165, 40mg/Day
Number of Participants With Hypersensitivity Adverse Reaction111119
SecondaryBlood Phenylalanine Concentration

Plasma phenylalanine (Phe) concentration

Time frame:
baseline and 36 weeks
Reported as:
Mean · umol/L
Blood Phenylalanine Concentration
umol/LBMN 165, 20mg/DayBMN 165, 40mg/Day
Baseline1241.0 ± 389.701224.4 ± 384.28
Week 36868.4 ± 501.78624.4 ± 530.58
Other pre-specifiedDietary Phenylalanine

All patients will complete a 3-day diet diary in order to assess dietary phenylalanine intake.

Time frame:
baseline and 36 weeks
Reported as:
Mean · mg
Dietary Phenylalanine
mgBMN 165, 20mg/DayBMN 165, 40mg/Day
Baseline1750.8 ± 1168.911647.9 ± 1222.68
Week 361851.8 ± 1145.062057.9 ± 1448.21

Adverse events

Collected over Week 0- Week 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMN 165, 20mg/Day1/131 (0.8%)7/131 (5.3%)130/131 (99.2%)
BMN 165, 40mg/Day0/130 (0%)19/130 (14.6%)129/130 (99.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventBMN 165, 20mg/DayBMN 165, 40mg/Day
Anaphylactic reactionImmune system disorders2/1316/130
HypersensitivityImmune system disorders0/1313/130
Anaphylactoid reactionImmune system disorders0/1312/130
AnxietyPsychiatric disorders0/1312/130
Pericardial effusionCardiac disorders0/1311/130
Puncture site haemorrhageGeneral disorders0/1311/130
Serum sicknessImmune system disorders1/1311/130
Gastroenteritis viralInfections and infestations0/1311/130
Pyelonephritis acuteInfections and infestations0/1311/130
Blood creatine phosphokinase increasedInvestigations1/1311/130
Most frequent other events
Showing 10 of 55
Most frequent other events
EventBMN 165, 20mg/DayBMN 165, 40mg/Day
ArthralgiaMusculoskeletal and connective tissue disorders78/13192/130
Injection site reactionGeneral disorders80/13168/130
Injection site erythemaGeneral disorders57/13161/130
HeadacheNervous system disorders46/13136/130
RashSkin and subcutaneous tissue disorders27/13140/130
Injection site pruritusGeneral disorders29/13136/130
UrticariaSkin and subcutaneous tissue disorders18/13130/130
Injection site painGeneral disorders27/13129/130
NauseaGastrointestinal disorders29/13122/130
Injection site rashGeneral disorders22/13128/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)BMN 165, 20mg/DayBMN 165, 40mg/DayTotal
Mean30.2 ± 8.6328.1 ± 8.7729.2 ± 8.75
Age, Customized
Age, Customized(Participants)BMN 165, 20mg/DayBMN 165, 40mg/DayTotal
16 - <18 years5611
18 - <66 years126124250
Sex: Female, Male
Sex: Female, Male(Participants)BMN 165, 20mg/DayBMN 165, 40mg/DayTotal
Female6268130
Male6962131
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMN 165, 20mg/DayBMN 165, 40mg/DayTotal
Hispanic or Latino617
Not Hispanic or Latino125128253
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BMN 165, 20mg/DayBMN 165, 40mg/DayTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American123
White130124254
Other022
Region of Enrollment
Region of Enrollment(Participants)BMN 165, 20mg/DayBMN 165, 40mg/DayTotal
United States131130261
08

Study locations

31 sites
  • University of California, Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • UCSF Benioff Children's Hospital Oakland
    Oakland, California 94609, United States
  • The Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • University of Florida Clinical Research Center
    Gainesville, Florida 32610, United States
  • University of Miami Health System
    Miami, Florida 33136, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Emory Universty
    Decatur, Georgia 30033, United States
  • Ann and Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Children's Hospital
    Indianapolis, Indiana 46202, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Weisskopf Child Evaluation Center / University of Louisville
    Louisville, Kentucky 40202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Washington University Center for Applied Research Sciences
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Cooper Health Systems
    Camden, New Jersey 08103, United States
  • Atlantic Health System - Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Icahn School of Medicine at Mount Sinai Medical Center
    New York, New York 10029, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • University Hospital Cleveland, Case Medical Center
    Cleveland, Ohio 44106, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134, United States
  • Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Health Science at Houston
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Bilder DA, Arnold GL, Dimmock D, Grant ML, Janzen D, Longo N, Nguyen-Driver M, Jurecki E, Merilainen M, Amato G, Waisbren S. Improved attention linked to sustained phenylalanine reduction in adults with early-treated phenylketonuria. Am J Med Genet A. 2022 Mar;188(3):768-778. doi: 10.1002/ajmg.a.62574. Epub 2021 Nov 26. PubMed 34826353 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 2 years 9 months after primary completion. A results delay was requested in Aug 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2013
First posted
Mar 28, 2013
Start
May 2013
Primary completionActual
Nov 25, 2015
CompletionActual
Nov 25, 2015
Results delay requested
Aug 17, 2017
Results first posted
Sep 10, 2018
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01819727
Responsible party
Sponsor
First posted
Mar 28, 2013
Start date
May 2013
Primary completion
Nov 25, 2015
Completion
Nov 25, 2015
Results posted
Sep 10, 2018
Last update
Feb 26, 2019

Study contacts

Markus Merilainen, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvaliase

Start the discussion